Phorm appoints Michael Alkin to the Board as Non-Executive Director

– SINGAPORE – Phorm (AIM: PHRM), a leading internet personalisation technology company, is pleased to announce the appointment of Mr Michael Alkin as a Non-Executive Director of the Company with immediate effect.

Mr Alkin is currently a Portfolio Manager of the Tullamore Fund at Hilton Capital Management, LLC. Prior to joining Hilton Capital, Mr Alkin worked for 17 years in the hedge fund industry, most recently as a Portfolio Manager at Kellner Capital, having previously spent 7 years at Knott Partners LP as a Senior Partner of its US$1.5 billion equity hedge fund. Prior Analyst and Portfolio Manager positions include Walker Smith Capital, Blackbird Capital Partners (of which he was co-founder), Gilder Gagnon Howe, RH Capital, Scout Capital, Zweig Dimenna and Windsor Partners. Mr Alkin is a graduate of Dowling College, Long Island, holding a B.B.A. in Accounting.

Kent Ertugrul, Chairman and CEO of Phorm, commented: “We are delighted to welcome Michael to the Phorm Board. His valuable experience of international capital markets and analytical skillset will assist us with the group’s future growth and development.”

About Phorm

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm’s innovative platform preserves user privacy and delivers a more interesting online experience.

Phorm’s industry leading technology enables its Internet Service Provider (“ISP”) partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

Phorm’s advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Phorm’s solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

Phorm’s partners include leading ISPs, Publishers, Advertising Networks and Advertisers.

Phorm, under a predecessor holding company, was admitted to the AIM market of the London Stock Exchange in 2004.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>

Talent4Boards
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.